Loading stock data…
$10.85+0.08 (+0.74%)
Kailera Therapeutics, Inc.
| Metric (USD) | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — |
| Operating Income | -$121.37M↓ | -$84.66M↓ | -$30.65M↓ | -$20.46M |
| Net Income | -$111.31M↓ | -$78.86M↓ | -$28.95M↓ | -$17.98M |
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectabl...